Abstract
Purpose
To explore whether topical antibiotic prophylaxis in patients scheduled for intravitreal injections achieves surface sterility in a greater proportion of subjects as compared to povidone-iodine alone.
Material and methods
A randomized, triple-blind clinical trial. Population: patients scheduled for intravitreal injections for maculopathy. Inclusion criteria: any sex and race, age 18 years and above. Subjects were randomized into 4 groups: the first group applied chloramphenicol (CHLORAM), the second netilmicin (NETILM), the third a commercial ozonized antiseptic solution (OZONE), and the fourth applied no drops (CONTROL). Outcome variable: percentage of non-sterile conjunctival swabs. Specimens were collected before and after the application of 5% povidone-iodine moments before the injection.
Results
Ninety-eight subjects (33.7% females, 64.3% males), mean age: 70.2 ± 9.3 years (54–91). Before povidone-iodine, both the CHLORAM and NETILM group showed a lower percentage of non-sterile swabs (61.1% and 31.3% respectively), as compared to the OZONE (83.3%) and CONTROL (86.5%) groups (p < .04). However, this statistical difference was lost after the application of povidone-iodine for 3 min. Percentage of non-sterile swabs in each group after applying 5% povidone-iodine: CHLORAM 11.1%, NETILM 12.5%, CONTROL 15.4%, OZONE 25.0%. This was not statistically significant (p > .05).
Conclusions
Topical antibiotic prophylaxis with chloramphenicol or netilmicin drops decreases the bacterial load on the conjunctiva. However, after the application of povidone-iodine, all groups showed a significant reduction in the percentage of non-sterile swabs, and this value was comparable among all groups. For this reason, authors conclude that povidone-iodine alone is sufficient and prior topical antibiotic prophylaxis is not indicated.
Similar content being viewed by others
Change history
28 June 2023
The given name and family name of the first author has been incorrectly identified in the XML version. This has been updated and corrected: "Edoardo" as given name and "Trovato Battagliola" as family name.
References
Pacella E, Pacella F, La Torre G, Impallara D, Malarska K, Brillante C, Turchetti P, De Giusti M (2012) Testing the effectiveness of intravitreal ranibizumab during 12 months of follow-up in venous occlusion treatment. Clin Ter 163(6):e413–e422
Casparis H, Wolfensberger TJ, Becker M, Eich G, Graf N, Ambresin A, Mantel I, Michels S (2014) Incidence of presumed endophthalmitis after intravitreal injection performed in the operating room: a retrospective multicenter study. (Retina Philadelphia, Pa) 34(1):12–17. https://doi.org/10.1097/IAE.0b013e31829f74b0
Freiberg FJ, Brynskov T, Munk MR, Sørensen TL, Wolf S, Wirth MA, Becker M, Michels S (2017) Low endophthalmitis rates after intravitreal anti-vascular endothelial growth factor injections in an operation room: a retrospective multicenter study. Retina (Philadelphia, Pa) 37(12):2341–2346. https://doi.org/10.1097/IAE.0000000000001488
Pacella F, Agostinelli E, Carlesimo SC, Nebbioso M, Secondi R, Forastiere M, Pacella E (2016) Management of anterior chamber dislocation of a dexamethasone intravitreal implant: a case report. J Med Case Reports 10(1):282. https://doi.org/10.1186/s13256-016-1077-2
Pacella F, Pacella E, Trovato Battagliola E, Malvasi M, Scalinci SZ, Turchetti P, Salducci M, Lucchino L, & Arrico L (2021). Efficacy and safety of intravitreal fluocinolone acetonide microimplant (ILUVIEN®) in patients with chronic diabetic macular edema: 1 year follow-up. European journal of ophthalmology, 11206721211020203. Advance online publication. https://doi.org/10.1177/11206721211020203
Morioka M, Takamura Y, Nagai K, Yoshida S, Mori J, Takeuchi M, Sawada T, Sone K, Fukuyama H, Kusuhara S, Yasukawa T, Murakami T, Tabuchi H, Nagasato D, Hirano T, Ueda T, Jujo T, Sasajima H, Mitamura Y, Ishikawa K, … Inatani M (2020). Incidence of endophthalmitis after intravitreal injection of an anti-VEGF agent with or without topical antibiotics. Sci Rep, 10(1), 22122. https://doi.org/10.1038/s41598-020-79377-w
Torres-Costa S, Ramos D, Brandão E, Carneiro Â, Rosas V, Rocha-Sousa A, Falcão-Reis F, Falcão M (2021) Incidence of endophthalmitis after intravitreal injection with and without topical antibiotic prophylaxis. Eur J Ophthalmol 31(2):600–606. https://doi.org/10.1177/1120672120902028
Pacella E, Loffredo L, Malvasi M, TrovatoBattagliola E, Messineo D, Pacella F, Arrico L (2020) Effects of repeated intravitreal injections of dexamethasone implants on intraocular pressure: a 4-year study. Clinical ophthalmology (Auckland, NZ) 14:3611–3617. https://doi.org/10.2147/OPTH.S265691
Hunyor AP, Merani R, Darbar A, Korobelnik JF, Lanzetta P, Okada AA (2018) Topical antibiotics and intravitreal injections. Acta Ophthalmol 96(5):435–441. https://doi.org/10.1111/aos.13417
Tanaka K, Shimada H, Mori R, Nakashizuka H, Hattori T, Okubo Y (2019) No increase in incidence of post-intravitreal injection endophthalmitis without topical antibiotics: a prospective study. Jpn J Ophthalmol 63(5):396–401. https://doi.org/10.1007/s10384-019-00684-5
Storey PP, Patel D, Garg S (2020) Endophthalmitis following intravitreal injection of anti-vascular endothelial growth factor agents Canadian journal of ophthalmology. Journal canadien d’ophtalmologie 55(4):286–292. https://doi.org/10.1016/j.jcjo.2020.01.015
Puustjärvi T, Teräsvirta M, Nurmenniemi P, Lokkila J, Uusitalo H (2006) Penetration of topically applied levofloxacin 0.5% and ofloxacin 0.3% into the vitreous of the non-inflamed human eye. Graefes Arch Clin Exp Ophthalmol= Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 244(12):1633–1637
Yalvac IS, Basci NE, Bozkurt A, Duman S (2003) Penetration of topically applied ciprofloxacin and ofloxacin into the aqueous humor and vitreous. J Cataract Refract Surg 29(3):487–491. https://doi.org/10.1016/s0886-3350(02)01538-9
Sakamoto H, Sakamoto M, Hata Y, Kubota T, Ishibashi T (2007) Aqueous and vitreous penetration of levofloxacin after topical and/or oral administration. Eur J Ophthalmol 17(3):372–376. https://doi.org/10.1177/112067210701700316
Cekic O, Batman C, Yasar U, Basci NE, Bozkurt A, Kayaalp SO (1998) Penetration of ofloxacin in human aqueous and vitreous humors following oral and topical administration. Retina (Philadelphia, Pa) 18(6):521–525. https://doi.org/10.1097/00006982-199806000-00005
Pacella E, La Torre G, Impallara D, Malarska K, Turchetti P, Brillante C, Smaldone G, De Paolis G, Muscella R, Pacella F (2013) Efficacy and safety of the intravitreal treatment of diabetic macular edema with pegaptanib: a 12-month follow-up. Clin Ter 164(2):e121–e126. https://doi.org/10.7417/CT.2013.1543
Kaldirim H, Yazgan S, Kirgiz A, Ozdemir B, Yilmaz A (2020) Effect of topical antibiotic prophylaxis on conjunctival flora and antibiotic resistance following intravitreal injections in patients with type 2 diabetes. Korean J Pphthalmol : KJO 34(4):265–273. https://doi.org/10.3341/kjo.2019.0144
Storey P, Dollin M, Rayess N, Pitcher J, Reddy S, Vander J, Hsu J, Garg S, & Post-Injection Endophthalmitis Study Team (2016) The effect of prophylactic topical antibiotics on bacterial resistance patterns in endophthalmitis following intravitreal injection. Graefe’s Arch Clin Exp Ophthalmol Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 254(2):235–242. https://doi.org/10.1007/s00417-015-3035-x
Pacella F, Collini S, Angelucci F, Agostinelli E, Guzzo AS, Cerza C, Pacella E (2017) Infections in hospital departments What is hospital responsibility? La Clinica terapeutica 168(4):e266–e270. https://doi.org/10.7417/T.2017.2018
Nelson RE, Hatfield KM, Wolford H, Samore MH, Scott RD, Reddy SC, Olubajo B, Paul P, Jernigan JA, Baggs J (2021) National estimates of healthcare costs associated with multidrug-resistant bacterial infections among hospitalized patients in the United States. Clin Infect Dis : Off Publ Infect Dis Soc Am 72(Suppl 1):S17–S26. https://doi.org/10.1093/cid/ciaa1581
De Sio S, Letizia C, Petramala L, Saracino V, Cedrone F, Sanguigni P, Buomprisco G, Perri R, TrovatoBattagliola E, Mannocci A, La Torre G (2018) Work-related stress and cortisol levels: is there an association? Results of an observational study. Eur Rev Med Pharmacol Sci 22(24):9012–9017. https://doi.org/10.26355/eurrev_201812_16672
Lepelletier D, Maillard JY, Pozzetto B, Simon A (2020) Povidone iodine: properties, mechanisms of action, and role in infection control and Staphylococcus aureus Decolonization. Antimicrob Agents Chemother 64(9):e00682-e720. https://doi.org/10.1128/AAC.00682-20
Stefanutti C, Mesce D, Pacella F, Di Giacomo S, Turchetti P, Forastiere M, TrovatoBattagliola E, La Torre G, Smaldone G, Pacella E (2019) Optical coherence tomography of retinal and choroidal layers in patients with familial hypercholesterolaemia treated with lipoprotein apheresis. Atheroscler Suppl 40:49–54. https://doi.org/10.1016/j.atherosclerosissup.2019.08.031
Avery RL, Bakri SJ, Blumenkranz MS, Brucker AJ, Cunningham ET Jr, DʼAmico DJ, Dugel PU, Flynn HW Jr, Freund KB, Haller JA, Jumper JM, Liebmann JM, McCannel CA, Mieler WF, Ta CN, & Williams GA (2014). Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina (Philadelphia, Pa.), 34 Suppl 12, S1–S18. https://doi.org/10.1097/IAE.0000000000000399
Bhatt SS, Stepien KE, Joshi K (2011) Prophylactic antibiotic use after intravitreal injection: effect on endophthalmitis rate. Retina (Philadelphia, Pa) 31(10):2032–2036. https://doi.org/10.1097/IAE.0b013e31820f4b4f
Abdolrahimzadeh S, Gharbiya M, Formisano M, Bertini F, Cerini A, Pacella E (2019) Anti-vascular endothelial growth factor intravitreal therapy and macular ganglion cell layer thickness in patients with neovascular age-related macular degeneration. Curr Eye Res 44(9):1000–1005. https://doi.org/10.1080/02713683.2019.1610179
Asghar A, Ellhai I, Obaid N, Sughra U (2018) Role of topical antibiotics in prophylaxis against endophthalmitis following intravitreal antibiotics. Pakistan J Med Sci 34(5):1283–1287. https://doi.org/10.12669/pjms.345.14817
Cheung CS, Wong AW, Lui A, Kertes PJ, Devenyi RG, Lam WC (2012) Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. Ophthalmology 119(8):1609–1614. https://doi.org/10.1016/j.ophtha.2012.02.014
Patel SN, Gangaputra S, Sternberg P Jr, Kim SJ (2020) Prophylaxis measures for postinjection endophthalmitis. Surv Ophthalmol 65(4):408–420. https://doi.org/10.1016/j.survophthal.2019.12.005
Storey PP, Tauqeer Z, Yonekawa Y, Todorich B, Wolfe JD, Shah SP, Shah AR, Koto T, Abbey AM, Morizane Y, Sharma P, Wood EH, Morizane-Hosokawa M, Pendri P, Pancholy M, Harkey S, Jeng-Miller KW, Obeid A, Borkar DS, Chen E, … Post-Injection Endophthalmitis (PIE) Study Group (2019). The impact of prefilled syringes on endophthalmitis following intravitreal injection of ranibizumab. Am J Ophthalmol, 199, 200–208. https://doi.org/10.1016/j.ajo.2018.11.023
Merani R, McPherson ZE, Luckie AP, Gilhotra JS, Runciman J, Durkin S, Muecke J, Donaldson M, Aralar A, Rao A, Davies PE (2016) Aqueous chlorhexidine for intravitreal injection antisepsis: a case series and review of the literature. Ophthalmology 123(12):2588–2594. https://doi.org/10.1016/j.ophtha.2016.08.022
Oakley CL, Vote BJ (2016) Aqueous chlorhexidine (0.1%) is an effective alternative to povidone-iodine for intravitreal injection prophylaxis. Acta ophthalmologica 94(8):e808–e809. https://doi.org/10.1111/aos.12981
Shimada H, Hattori T, Mori R, Nakashizuka H, Fujita K, Yuzawa M (2013) Minimizing the endophthalmitis rate following intravitreal injections using 0.25% povidone-iodine irrigation and surgical mask. Graefes Arch Clin Exp Ophthalmol Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 251(8):1885–1890. https://doi.org/10.1007/s00417-013-2274-y
McDonnell G, Russell AD (1999) Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev 12(1):147–179. https://doi.org/10.1128/CMR.12.1.147
Author information
Authors and Affiliations
Contributions
Edoardo, Trovato Battagliola, MD: Writing—original draft.
Rodolfo Javier, Riveros Cabral, MD: Data curation.
Gregorio Manco, MD: Project administration.
Gianluca Puggioni: Investigation, data curation.
Claudio Brancato, MD: Investigation, data curation.
Pietro Mangiantini, MD: Formal analysis.
Floriana Testa, MD: Visualization.
Mariaelena Malvasi, MD: Visualization.
Giammarco Raponi, MD: Supervision.
Paolo Turchetti, MD: Methodology.
Fernanda Pacella, MD. Methodology.
Elena Pacella, MD: Conceptualization, writing—review and editing, supervision.
Corresponding author
Ethics declarations
Ethical approval
This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Sapienza University of Rome (Nov. 8th, 2021/No. 345235).
Informed consent
Informed consent was obtained from all individual participants included in the study.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Trovato Battagliola, E., Riveros Cabral, R.J., Manco, G. et al. Topical antibiotic prophylaxis before intravitreal injections: a pilot study. Graefes Arch Clin Exp Ophthalmol 261, 2953–2959 (2023). https://doi.org/10.1007/s00417-023-06113-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-023-06113-1